MedDRA: An overview of the medical dictionary for regulatory activities

被引:34
作者
Mozzicato P. [1 ]
机构
[1] MedDRA Maintenance and Support Services Organization, Northrop Grumman Information Systems, Chantilly, VA 20151
关键词
Biopharmaceutical Industry; Uppsala Monitoring Centre; Individual Case Safety Report; Periodic Safety Update Report; Lower Level Term;
D O I
10.1007/BF03256752
中图分类号
学科分类号
摘要
The Medical Dictionary for Regulatory Activities (MedDRA) is a multi-axial, five-tiered hierarchical terminology used by regulatory authorities and the biopharmaceutical industry for the coding (classification) of clinical data in adverse eventadverse drug reaction (AEADR) reports. The terminology developed by the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) is maintained by an independent organization that distributes MedDRA via subscription. The activities of this organization the Maintenance and Support Services Organization are overseen by the MedDRA Management Board, which itself reports to the ICH Steering Committee.MedDRA was developed to overcome some of the limitations of previous AEADR coding terminologies and to provide a single, multilingual resource for the classification of AEADR data. Currently, MedDRAs use is mandated for various types of regulatory reporting in the EU and Japan; it is widely used by the biopharmaceutical industry in all three ICH regions (US, EU and Japan). The US Food and Drug Administration has used MedDRA in its Adverse Event Reporting System for over a decade.MedDRA provides a robust, vigorously maintained standard terminology for AEADR reporting with sufficient granularity of concepts and logical medical groupings within its hierarchy of terms. However, because of the size and specificity of MedDRA, as well as the organization of some of its groupings, retrieval and aggregation of coded AEADR data can sometimes present a challenge. Standardised MedDRA Queries (SMQs) have been developed in part to address this challenge. As of the time of writing, there are nearly 70 SMQ topics available to MedDRA users.MedDRAs use continues to expand 10 years after its official launch, driven primarily by the needs of and input from its user community. © 2009 Adis Data Information BV. All rights reserved.
引用
收藏
页码:65 / 75
页数:10
相关论文
共 17 条
  • [1] Introductory Guide, MedDRA version 12.0
  • [2] Mozzicato P., MedDRA - Past and future, Regul Aff J Pharma, 17, 12, pp. 797-805, (2006)
  • [3] Wood K.L., Themedical dictionary for drug regulatory affairs (MEDDRA) project, Pharmacoepidemiol Drug Saf, 3, pp. 7-13, (1994)
  • [4] Brown E.G., Wood K.L., Wood S.M., The medical dictionary for regulatory activities (MedDRA), Drug Saf, 20, 2, pp. 109-117, (1999)
  • [5] Cone M., Regulatory update: The long-awaited MedDRA has arrived!, Good Clin Pract J, 6, 1, pp. 42-43, (1999)
  • [6] Huntley K., Veverka M.J., Golden M., The FDA's medical dictionary for drug regulatory affairs alpha test, Drug Inf J, 29, 4, pp. 1133-1143, (1995)
  • [7] MedDRA Term Selection: Points to Consider, Release 3.12
  • [8] MedDRA Data Retrieval and Presentation: Points to Consider, Release 2.0
  • [9] Zhao-Wong A., Rump E., Moraleda T., Et al., Proposed terminology changes to facilitate the analysis of MedDRA-coded data, Drug Inf J, 40, pp. 291-303, (2006)
  • [10] Brown E.G., Effects of coding dictionary on signal generation: A consideration of the use of MedDRA compared with WHO-ART, Drug Saf, 25, 6, pp. 445-452, (2002)